Advertisement

Pharmaceutisch Weekblad

, Volume 14, Issue 4, pp 258–267 | Cite as

New cytotoxic drugs and targets in oncology

  • J. H. Beijnen
Drugs in the Pipeline

Abstract

New agents in the preclinical and early clinical pipeline (phases I and II) are described and some of the problems associated with their development are reviewed. The article focuses on tubulin poisons such as taxol, topoisomerase inhibitors, such as topotecan, and drugs such as bryostatin 1 and miltefosin, which interfere with specific signal transduction pathways involved in malignant cell growth.

Keywords

Bryostatin 1 New cytotoxic drugs Signal transduction Taxol Topoisomerase inhibitors Topotecan Tubulin poisons 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schwartsmann G, Winograd B, Pinedo HM. The main steps in the development of anticancer agents. Radiother Oncol 1988;12:301–13.PubMedGoogle Scholar
  2. 2.
    Johnson RK. Screening methods in antineoplastic drug discovery. J Natl Cancer Inst 1990;82:1083–4.PubMedGoogle Scholar
  3. 3.
    Kopka ML, Yoon C, Goodsell D, Pjura P, Dickerson RE. The molecular origin of DNA-drug specificity in netropsin and distamycin. Proc Natl Acad Sci 1985;82: 1376–80.PubMedGoogle Scholar
  4. 4.
    Aristoff PA, Warpehoski MA, Kelly RC, Mitchell MA, Krueger WC, McGovern JP, Li LH. Utilization of mechanism of action and structure — activity information in the rational design of highly efficacious CC-1065 analogs. Abstract 062. Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, March 7–10, 1989.Google Scholar
  5. 5.
    Beijnen JH. Report on the Formulation of U-80,244. New Drug Development Office-European Organization of Research and Treatment of Cancer (NDDO-EORTC), Amsterdam, 1990.Google Scholar
  6. 6.
    Broggini M, Ponti M, Ottolenghi S, D'Incalci M, Mongelli N, Mantovani R. Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements. Nucl Acid Res 1989;17:1051–9.Google Scholar
  7. 7.
    Pettit GR, Day JF, Hartwell JL, Wood HG. Antineoplastic components of marine animals. Nature 1970; 227:962–3.PubMedGoogle Scholar
  8. 8.
    Pettit GR, Kamano Y, Brown P, Gust D, Inoue M, Herald CL. Structure of the cyclic peptide dolastatin 3 fromDolabella auricularia. J Am Chem Soc 1982;104:905–7.Google Scholar
  9. 9.
    Pettit GR, Herald CL, Doubek DL, Herald DL. Isolation of bryostatin 1. J Am Chem Soc 1982;104:6846–8.Google Scholar
  10. 10.
    Lavelle F, Zerial A, Fizames C, Rabault B, Curaudeau A. Antitumor activity and mechanism of action of the marine compound girodazole. Invest New Drugs 1991;9:233–44.PubMedGoogle Scholar
  11. 11.
    Chun HG, Davies B, Hoth D, Suffness M, Plowman J, Flora K, et al. Didemnin B: the first marine compound entering clinical trials as an antineoplastic agent. Invest New Drugs 1986;4:279–84.PubMedGoogle Scholar
  12. 12.
    Stewart JA, Low JB, Roberts JD, Blow A. A phase I trial of didemnin B. Cancer 1991;68:2550–5.PubMedGoogle Scholar
  13. 13.
    Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, et al. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 1991;253:562–5.PubMedGoogle Scholar
  14. 14.
    Tidd DM, Hawley P, Warenius HM, Gibson I. Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence methylphosphonate oligonucleotide analogues. Anticancer Drug Des 1988;3:117–27.PubMedGoogle Scholar
  15. 15.
    Rosenberg SA, Aebersold P, Cornetta K, Kasid A, et al. Gene transfer into humans-Immunotherapy of patients with advanced melanoma, using tumorinfiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323:570–8.PubMedGoogle Scholar
  16. 16.
    Kaye SB. New drug development. Eur J Cancer 1991;27:377–80.PubMedGoogle Scholar
  17. 17.
    Workman P. Philosophies of new anticancer drug development. J Drug Dev 1990;2:193–7.Google Scholar
  18. 18.
    Workman P. New drugs and novel agents. Curr Opin Oncol 1989;1:213–21.PubMedGoogle Scholar
  19. 19.
    Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant Antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent fromTaxus brevifolia. J Am Chem Soc 1971;93: 2325–7.PubMedGoogle Scholar
  20. 20.
    Senilh V, Blechert S, Colin M, Guenard D, Picot F, Potier P, Varenne P. Mise en evidence de nouveaux analogues du taxol extraints deTaxus baccata. J Natl Prod 1984;47:131–7.Google Scholar
  21. 21.
    De Brabander M, Geuens G, Nuydens R, Willebrords R, De Mey J. Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci USA 1981;78:5608–12.PubMedGoogle Scholar
  22. 22.
    Manfredi JJ, Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmac Ther 1984;25:83–125.Google Scholar
  23. 23.
    Horwitz SB, Lothstein L, Manfredi JJ, Mellado W, Parness J, Roy SN, et al. Taxol: Mechanisms of action and resistance. Ann NY Acad Sci 1986;466:733–44.PubMedGoogle Scholar
  24. 24.
    Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antineoplastic agent. J Natl Cancer Inst 1990;82:1257–9.Google Scholar
  25. 25.
    Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991;9:1704–12.PubMedGoogle Scholar
  26. 26.
    Thigpen T, Blessing J, Ball H, Hummel S, Barret R. Phase II trial of taxol as second-line therapy for ovarian carcinoma: a gynecologic oncology group study. Proc Am Soc Clin Oncol 1990;9:604.Google Scholar
  27. 27.
    Einzig AI, Wiernik PH, Sasloff J, Carl S, Runcwicz C, O'Hanlan KA, et al. Phase II study of taxol in patients with advanced ovarian cancer. Proc Am Assoc Cancer Res 1990;31:114.Google Scholar
  28. 28.
    McGuire WP, Rowinski EK, Rosenshein NB, et al. Taxol, a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273–9.PubMedGoogle Scholar
  29. 29.
    Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A phase II trial of taxol in metastatic melanoma. Cancer 1990;65:2478–81.PubMedGoogle Scholar
  30. 30.
    Weiss RB, Donehower RC, Wiernik PH, Ohnumo T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263–8.PubMedGoogle Scholar
  31. 31.
    Waugh WN, Trissel LA, Stella VJ. Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm 1991;48:1520–4.PubMedGoogle Scholar
  32. 32.
    Bissery MC, Baysass M, Lavell F. Preclinical evaluation of intravenous taxotere. Proc Am Assoc Cancer Res 1990;31:447.Google Scholar
  33. 33.
    Gentry R. Intensive effort under way to develop taxol supplies. J Natl Cancer Inst 1991;83:603–4.Google Scholar
  34. 34.
    Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991;9:1692–703.PubMedGoogle Scholar
  35. 35.
    Wang JC. DNA topoisomerases. Ann Rev Biochem 1985;54:665–97.PubMedGoogle Scholar
  36. 36.
    Epstein RJ. Topoisomerases in human disease. Lancet 1988;1:512–4.PubMedGoogle Scholar
  37. 37.
    Wang JC, DNA topoisomerases: from a laboratory curiosity to a subject in cancer chemotherapy. NCI Monographs 1987;4:3–6.PubMedGoogle Scholar
  38. 38.
    Schaeppi U, Fleischmann RW, Cooney DA. Toxicity of camptothecin. Cancer Chemother Rep Part 3 1974;5:25–36.Google Scholar
  39. 39.
    Negoro S, Fukuoka M, Niitani H, Taguchi T. Phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1991;10:241.Google Scholar
  40. 40.
    Beijnen JH, Smith BR, Keijer WJ, Van Gijn R, Ten Bokkel Huinink WW, et al. High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J Pharm Biomed Anal 1990;8:789–94.PubMedGoogle Scholar
  41. 41.
    Underberg WJM, Goossen RMJ, Smith BR, Beijnen JH. Equilibrium kinetics of the new experimental anti-tumour drug SK&F 104864-A in aqueous solution. J Pharm Biomed Anal 1990;8:681–3.PubMedGoogle Scholar
  42. 42.
    Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, et al. DNA Topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989;246:1046–8.PubMedGoogle Scholar
  43. 43.
    Einhorn LH. Daily oral etoposide in the treatment of cancer. Semin Oncol 1991;18 Suppl 2:43–7.PubMedGoogle Scholar
  44. 44.
    Casper E, Magill M, Freidrich C, Gaynor J, Hajdu S, Brennan M. Prospective randomized trial of adjuvant adriamycin (A) by bolus (B) vs 72-hour continuous infusion (CI) in patients (PTS) with high grade soft tissue sarcoma (HGS). Proc Am Soc Clin Oncol 1989;8:320.Google Scholar
  45. 45.
    Beiling P, Winkler K, Bielack S, Delling G, Kotz R, Gadner H, et al. Continuous infusion (CI) versus short term infusion (SI) of doxorubicin (DOX) in osteosarcoma (OS). Proc Am Soc Clin Oncol 1991;10:308.Google Scholar
  46. 46.
    Weinberg RA. Tumor suppressor genes. Science 1991;254:1138–46.PubMedGoogle Scholar
  47. 47.
    Druker BJ, Mamon HJ, Roberts TM. Oneogenes, growth factors, and signal transduction. N Engl J Med 1989;321:1383–91.PubMedGoogle Scholar
  48. 48.
    Roberts AB, Sporn MB. Principles of molecular cell biology of cancer: growth factors related to transformations. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 3rd ed. Philadelphia: J.B. Lippincott Company, 1990:67–80.Google Scholar
  49. 49.
    Powis G. Signalling targets for anticancer drug development. TiPS 1991;12:188–94.PubMedGoogle Scholar
  50. 50.
    Nishizuka Y. The molecular heterogeinity of protein kinase C and its implications for cellular regulation. Nature 1988;334:661–5.PubMedGoogle Scholar
  51. 51.
    Blumberg PM. Protein kinase C as the receptor for the phorbol ester tumor promotors: sixth Rhoads memorial award lecture. Cancer Res 1988;48:1–8.PubMedGoogle Scholar
  52. 52.
    Grunicke HH. The cell membrane as a target for cancer chemotherapy. Eur J Cancer 1991;27:281–4.PubMedGoogle Scholar
  53. 53.
    Cuttitta F, Carney DN, Mulshine J, et al. Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature 1985;316: 823–6.PubMedGoogle Scholar
  54. 54.
    Woll PJ, Rozengurt E. Bombesin and bombesin antagonists: studies in Swiss 3T3 cells and human small cell lung cancer. Br J Cancer 1988;57:579–86.PubMedGoogle Scholar
  55. 55.
    Woll PJ, Rozengurt E. [D-Arg1,D-Phe5,-Trp7'9,Leu11]substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cellsin vitro. Proc Natl Acad Sci USA 1988;85:1859–63.PubMedGoogle Scholar
  56. 56.
    Mahmoud S, Staley J, Taylor J, et al. Inhibition of lung tumour growth by bombesin analogues. Cancer Res 1991;51:1798–801.PubMedGoogle Scholar
  57. 57.
    Matuoka K, Fukami K, Nakanishi O, Kawai S, Takenawa T. Mitogenesis in response to PDGF and bombesin abolished by microinjection of antibody to PIP2. Science 1988;239:640–2.PubMedGoogle Scholar
  58. 58.
    Berdel WE. Ether lipids and derivatives as investigational anticancer drugs. Onkologie 1990;13:245–50.PubMedGoogle Scholar
  59. 59.
    Berdel WE, Fink U, Rastetter J. Clinical phase I pilot study of the alkyl-lysophospholipid derivative ET-18-OCH3. Lipids 1987;22:967–9.PubMedGoogle Scholar
  60. 60.
    Unger C, Eibl H, Nagel GA, Von Heyden HW, Breiser A, Engel J, et al. Hexadecylphosphocholine in the topical treatment of skin metastases: a phase I trial. Contrib Oncol 1989;37:219–23.Google Scholar
  61. 61.
    Housey GM, Johnson MD, Wendy Hsiao WL, O'Brian CA, Murphy JP, Kirschmeier P, et al. Overproduction of protein kinase C causes disordered growth control in rat fibroblasts. Cell 1988;52:343–54.PubMedGoogle Scholar
  62. 62.
    Persons DA, Wilkison WO, Bell RM, Finn OJ. Altered growth regulation and enhanced tumorigenicity of NIH 3T3 fibroblasts transfected with protein kinase C-1 cDNA. Cell 1988;52:447–58.PubMedGoogle Scholar
  63. 63.
    Crowther D. Phase I study of bryostatin-1; a new protein kinase C modulator with antitumour properties [Abstract]. EORTC-New Drug Symposium, June 26–29, 1991, Vienna, Austria.Google Scholar
  64. 64.
    Gescher A. Protein kinase C: preclinical aspects [Abstract]. EORTC-New Drug Symposium, June 26–29, 1991, Vienna, Austria.Google Scholar
  65. 65.
    Van Rijswijk REN, Horenblas S, Wagstaff J, Van Loenen AC, Beijnen JH, Pinedo HM. Suramin in hormone-resistant prostate carcinoma. Tijdschr NVKC 1992;17:43–7.Google Scholar
  66. 66.
    Stein CA, LaRocca R, McAtee RT, Myers CE. Suramin: an anticancer drug with an unique mechanism of action. J Clin Oncol 1989;7:499–508.PubMedGoogle Scholar
  67. 67.
    Harland S, Duchesne G. Suramin and prostate cancer: the role of hydrocortisone [Abstract]. EORTC-PAM Winter Meeting, January 8–11, 1992, Bologna, Italy.Google Scholar
  68. 68.
    Larsen AK. Modulation of topoisomerase susceptibility by compounds acting on signal transduction [Abstract]. EORTC-PAM Winter Meeting, January 8–11, 1992, Bologna, Italy.Google Scholar
  69. 69.
    Lopez RL, Peters GJ, Pizao PE, Van Rijswijk REN, Wagstaff J, Pinedo HM. Suramin affects intracellular calcium concentration, protein kinase C and cell cycle distribution. NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam; March 17–20. 1922: Abstract 024:64.Google Scholar
  70. 70.
    Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe SI, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987;262:5592–5PubMedGoogle Scholar
  71. 71.
    Scambia G, Ranelletti FO, Panici PB, Piantelli M, Bonanno G, De Vincenzo R, et al. Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites. Cancer Chemother Pharmacol 1991;28:255–8.PubMedGoogle Scholar
  72. 72.
    Gazit A, Yaigh P, Gilon D, Levitzky A. Tryphostins I: synthesis and biological activity of protein kinase inhibitors. J Med Chem 1989;32:2344–52.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1992

Authors and Affiliations

  • J. H. Beijnen
    • 1
  1. 1.Slotervaart Hospital/Netherlands Cancer InstituteEC Amsterdamthe Netherlands

Personalised recommendations